KMDA reported results of phase-2/3 inhaled AAT trial: http://finance.yahoo.com/news/kamada-announces-preliminary-results-phase-113000181.html Missed the primary (time to first moderate or severe exacerbation) and hit one secondary endpoint (frequency of severe exacerbation).